Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979515066> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2979515066 abstract "Abstract Abstract SCI-48 Adoptive transfer of T cells can lead to targeted and long-lived anti-tumor or anti-infective activity and can also modulate alloreactivity. T cell therapies have been used in both autologous and allogeneic settings. Donor-derived cytotoxic specific T lymphocytes (CTLs) have already proved highly effective in preventing or treating viral infections and Epstein-Barr virus (EBV) lymphomas developing after allogeneic hemopoietic stem cell transplant while T cells expanded ex vivo with CD3/28 beads have enhanced immune reconstitution after autologous stem cell transplantation. Clinical responses have also been observed following T cell therapy in patients with melanoma, lymphoma or nasopharyngeal cancer. Although successes have been obtained, these studies have also provided insights into the requirements for more effective cellular immunotherapy, which may be obtained by genetic modification of T cells. Approaches under evaluation in the clinic include transfer of artificial T cell receptors to target tumor cells, transfer of genes to render T cells resistant to tumor evasion mechanisms and transfer of a suicide gene that can be activated should adverse effects occur to allow the cell to be destroyed on exposure to a specific signal. The suicide gene strategy using the herpes simplex viral thymidine kinase (Tk) gene allows ablation of infused donor T cells if they induce graft-versus-host disease after allogeneic HSCT and has reached phase III clinical trial. In all these adoptive T cell immunotherapy strategies, broader application is limited by suboptimal persistence of transferred T cells, and by the complexity of current manufacturing techniques. Current research focuses on defining the optimum type of cell for transfer and the ex vivo selection and expansion procedures that favor long term persistence, since broader applicability will require ex vivo expanded T cells to show clinical activity and to have robust manufacturing processes and a clinical distribution paradigm. Strategies for simplifying and accelerating manufacture of T cell products have included the use of artificial antigen presenting cells expressing co-stimulatory ligands to provide a rapid source of antigen and optimized costimulation; bioreactors to grow cells in a closed system; and cytokine combinations to optimize cell growth and survival. Integration of these multiple approaches will be required to determine the best cell type and culture conditions for generating T cells for subsequent adoptive transfer into a complex immune network. Disclosures: Off Label Use: T cell products in studies conducted under INDs." @default.
- W2979515066 created "2019-10-18" @default.
- W2979515066 creator A5021029688 @default.
- W2979515066 date "2010-11-19" @default.
- W2979515066 modified "2023-09-26" @default.
- W2979515066 title "Expansion of Lymphocytes for Cell-Based Therapeutics" @default.
- W2979515066 doi "https://doi.org/10.1182/blood.v116.21.sci-48.sci-48" @default.
- W2979515066 hasPublicationYear "2010" @default.
- W2979515066 type Work @default.
- W2979515066 sameAs 2979515066 @default.
- W2979515066 citedByCount "0" @default.
- W2979515066 crossrefType "journal-article" @default.
- W2979515066 hasAuthorship W2979515066A5021029688 @default.
- W2979515066 hasConcept C203014093 @default.
- W2979515066 hasConcept C70721500 @default.
- W2979515066 hasConcept C71924100 @default.
- W2979515066 hasConcept C86803240 @default.
- W2979515066 hasConceptScore W2979515066C203014093 @default.
- W2979515066 hasConceptScore W2979515066C70721500 @default.
- W2979515066 hasConceptScore W2979515066C71924100 @default.
- W2979515066 hasConceptScore W2979515066C86803240 @default.
- W2979515066 hasLocation W29795150661 @default.
- W2979515066 hasOpenAccess W2979515066 @default.
- W2979515066 hasPrimaryLocation W29795150661 @default.
- W2979515066 hasRelatedWork W117823598 @default.
- W2979515066 hasRelatedWork W1948401147 @default.
- W2979515066 hasRelatedWork W1987531755 @default.
- W2979515066 hasRelatedWork W2003696220 @default.
- W2979515066 hasRelatedWork W2060957407 @default.
- W2979515066 hasRelatedWork W2073740449 @default.
- W2979515066 hasRelatedWork W2078599357 @default.
- W2979515066 hasRelatedWork W2133566973 @default.
- W2979515066 hasRelatedWork W2138058853 @default.
- W2979515066 hasRelatedWork W2164764205 @default.
- W2979515066 hasRelatedWork W2474714119 @default.
- W2979515066 hasRelatedWork W2538566824 @default.
- W2979515066 hasRelatedWork W25462431 @default.
- W2979515066 hasRelatedWork W2766206231 @default.
- W2979515066 hasRelatedWork W2770578347 @default.
- W2979515066 hasRelatedWork W2776478562 @default.
- W2979515066 hasRelatedWork W2944038179 @default.
- W2979515066 hasRelatedWork W2958772582 @default.
- W2979515066 hasRelatedWork W3006452743 @default.
- W2979515066 hasRelatedWork W2163950505 @default.
- W2979515066 isParatext "false" @default.
- W2979515066 isRetracted "false" @default.
- W2979515066 magId "2979515066" @default.
- W2979515066 workType "article" @default.